Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | PTGES | O14684 | 4/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456953 | 0.95 | LMNA (0.79) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL13064487 | 0.92 | LMNA (0.69) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL13064390 | 0.90 | LMNA (0.62) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL1711103 | 0.90 | HPGD (0.70) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL13065006 | 0.88 | LMNA (0.91) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL303307 | 0.87 | LMNA (0.71) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL3275402 | 0.85 | LMNA (0.64) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL304361 | 0.85 | LMNA (0.64) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL304397 | 0.84 | HPGD (0.80) | LMNAHPGDKMT2APTGESALOX5 | |
| SCHEMBL13064393 | 0.83 | LMNA (0.60) | LMNAHPGDKMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | claimed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | claimed |
| JP-2012500834-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | claimed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | claimed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | LMNA 1683/4885HPGD 3739/4885KMT2A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.